Dr. Ramesh Subramani brings over two decades of international experience in nonclinical drug discovery and development, toxicology consulting, chemical safety assessment and regulatory strategy for pharmaceutical, biotech, medial device and chemical industries.
As an independent toxicology consultant, Dr. Subramani provides expert guidance in designing and reviewing preclinical studies, ensuring regulatory compliance, risk-based toxicological evaluations, and strategic dossier support for global market authorizations.
Providing scientific and regulatory insights to support early-stage compound selection, lead optimization, and IND-enabling studies.
Expert design, review, and interpretation of GLP-compliant in vitro and in vivo toxicology studies, reducing risk and enhancing data quality.
Strategic nonclinical development roadmaps for IND, NDA, BLA, and international regulatory filings (US FDA, EMA, DCGI, ECHA, EFSA, MHRA, BfArM, ANVISA, Japan and more).
In-depth support for setting up or optimizing Good Laboratory Practice (GLP) systems in accordance with OECD principles of GLP for the regulatory toxicology studies.
Comprehensive safety evaluations including PDE (Permitted Daily Exposure), OEL (Occupational Exposure Limits), E&L (Extractables & Leachables), ERA (Environmental Risk Assessment), Nitrosamines (NDSRIs), QSAR-based predictions (ICHM7), Carcinogenicity, and genotoxic impurity assessments.
Scientific justification and qualification of impurities, degradants, and excipients in compliance with global regulatory expectations
Detailed data analysis, risk assessments, and expert summaries for inclusion in CTD modules for regulatory submissions across markets.
His global experience and affiliations ensure current, science-based, and compliant strategies for your drug/chemical safety programs.